• Sensex77303.63639.42(0.83%)
  • Nifty24092.7194.75(0.81%)
  • USDINR94.30.22(0.22%)
Online tarding Partner With Us
BSE Prices delayed by 5 minutes ! Prices as on   Apr 27, 2026   ABB India 7431.85 [ 1.43% ]ACC 1440.15 [ 2.03% ]Ambuja Cements 460.5 [ 2.19% ]Asian Paints 2484.9 [ 0.02% ]Axis Bank 1324.5 [ -3.05% ]Bajaj Auto 9662.65 [ 0.90% ]Bank of Baroda 273.95 [ -0.09% ]Bharti Airtel 1819.5 [ 0.26% ]Bharat Heavy 348.65 [ 3.35% ]Bharat Petroleum 313.25 [ 1.69% ]Britannia Industries 5718.45 [ -0.24% ]Cipla 1317.15 [ 1.73% ]Coal India 452.9 [ -0.65% ]Colgate Palm 2139.65 [ -1.52% ]Dabur India 452.35 [ 0.04% ]DLF 592.7 [ 0.93% ]Dr. Reddy's Lab. 1334.55 [ 1.42% ]GAIL (India) 165.7 [ 0.06% ]Grasim Industries 2778 [ 1.44% ]HCL Technologies 1228.7 [ 2.12% ]HDFC Bank 789.9 [ 0.64% ]Hero MotoCorp 5046.15 [ 1.67% ]Hindustan Unilever 2327.6 [ -0.06% ]Hindalco Industries 1061.9 [ 1.31% ]ICICI Bank 1315.05 [ -0.85% ]Indian Hotels Co. 647.75 [ 1.90% ]IndusInd Bank 899.95 [ 6.09% ]Infosys 1169.95 [ 1.34% ]ITC 303.9 [ 0.76% ]Jindal Steel 1277.75 [ 1.72% ]Kotak Mahindra Bank 376.9 [ 1.54% ]L&T 4050.85 [ 0.92% ]Lupin 2324.25 [ 1.23% ]Mahi. & Mahi 3102.6 [ 2.13% ]Maruti Suzuki India 13225.65 [ 1.37% ]MTNL 31.72 [ 3.73% ]Nestle India 1416.3 [ -0.33% ]NIIT 72.15 [ 5.19% ]NMDC 90.42 [ 1.34% ]NTPC 410.2 [ 2.12% ]ONGC 285.85 [ 0.39% ]Punj. NationlBak 113.9 [ 0.84% ]Power Grid Corpn. 320.85 [ 1.45% ]Reliance Industries 1365.95 [ 2.88% ]SBI 1111.8 [ 0.94% ]Vedanta 742.6 [ 2.98% ]Shipping Corpn. 290.4 [ 0.73% ]Sun Pharmaceutical 1733.8 [ 7.03% ]Tata Chemicals 722.55 [ 4.10% ]Tata Consumer 1159.7 [ -1.21% ]Tata Motors Passenge 354.15 [ 1.11% ]Tata Steel 213.5 [ 1.67% ]Tata Power Co. 453.4 [ 4.31% ]Tata Consult. Serv. 2447.45 [ 2.09% ]Tech Mahindra 1395.9 [ 2.64% ]UltraTech Cement 12013.2 [ 0.02% ]United Spirits 1392.05 [ 0.05% ]Wipro 205.05 [ 2.83% ]Zee Entertainment 91.43 [ 3.80% ]
BSE

MARKETS

News Details

( As on 23/04/2026 11:09)

Cipla Limited gets USFDA nod for first generic of Ventolin HFA

Cipla Limited, along with its subsidiary Cipla USA Inc., has received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol (90 mcg).

The approval marks the launch of the first AB-rated generic equivalent of Ventolin HFA, originally marketed by GlaxoSmithKline. The inhaler is used to treat and prevent bronchospasm in patients aged four years and above, including those with reversible airway diseases and exercise-induced bronchospasm.

With the U.S. albuterol market estimated at around $1.5 billion, this approval strengthens Cipla’s respiratory portfolio and solidifies its presence in the inhalation segment, where it now offers generics for both Ventolin HFA and Proventil HFA.

Managing Director and Global CEO Achin Gupta said the milestone highlights the company’s strong capabilities in complex inhalation therapies and its commitment to expanding a differentiated global respiratory portfolio.

The product will be manufactured at Cipla’s dedicated inhalation facility in Fall River, Massachusetts, supporting its strategy to enhance supply resilience and expand its U.S. manufacturing footprint.